About Oxford Biomedica PLC

Oxford Biomedica PLC (LSE:OXB), commonly known as OXB, is a global cell and gene therapy contract development and manufacturing organisation (CDMO).

Rather than relying primarily on developing its own medicines, OXB provides viral-vector development and manufacturing capabilities to biotechnology and pharmaceutical companies developing cell and gene therapies.

The company has built a multi-vector, multi-site manufacturing network spanning the UK, United States and France, positioning it to support customers from early development through commercial-scale manufacturing.

OXB describes itself as a quality- and innovation-led viral-vector CDMO whose mission is to enable clients to deliver advanced therapies.

Why Is Oxford Biomedica Up Today (28 July 2026)?

According to the market data you provided, Oxford Biomedica PLC shares are up approximately 1.93% today (28 July 2026).

The important point is that I could not verify a fresh material company announcement dated 28 July 2026 that clearly explains today's 1.93% increase.

OXB's investor calendar says a Half Year 2026 Trading Update is scheduled for July/August 2026, while its formal half-year results for the six months ended 30 June 2026 are scheduled for 22 September 2026.

That upcoming trading update may be contributing to investor positioning, but without a fresh announcement it would be speculative to say it caused today's gain.

Instead, today's rise comes against a fundamentally stronger backdrop: rapid revenue growth, a move into operating EBITDA profitability, substantial 2026 growth expectations and expanded US manufacturing capacity.

Key Highlights

Oxford Biomedica's FY2025 revenue was expected to reach approximately £166–169 million, representing roughly 30% year-on-year growth from £128.8 million in FY2024.

Management subsequently set FY2026 revenue guidance of £220–240 million on a constant-currency basis.

OXB expects an Operating EBITDA margin of around 10% for FY2026, followed by at least 20% in FY2027.

Management is also targeting 25–30% annual revenue growth in both FY2027 and FY2028, which would keep the company on a relatively rapid expansion trajectory.

Longer term, OXB sees potential for its Operating EBITDA margin to approach approximately 30% over five to six years as manufacturing capacity utilisation improves.

Key Reasons Behind Today's 1.93% Uptick

1. Expectations Ahead of the H1 2026 Trading Update

One potential short-term factor is anticipation surrounding Oxford Biomedica's next trading update.

The company's investor calendar identifies a Half Year 2026 Trading Update for July/August, although no exact date is currently specified on that page.

With investors expecting an update relatively soon, positioning ahead of the announcement could contribute to daily volatility.

However, this remains an interpretation rather than a confirmed explanation for today's 1.93% gain.

2. Strong FY2026 Revenue Expectations

OXB expects FY2026 revenue of £220–240 million, representing another substantial increase following rapid growth during FY2025.

At the midpoint, this would imply approximately £230 million of revenue.

The scale of expected growth is important because OXB has spent heavily developing a global manufacturing network. Higher revenue should improve utilisation of those facilities.

3. Transition Toward Higher Profitability

The investment story is increasingly moving beyond revenue growth toward margin expansion.

OXB expects its Operating EBITDA margin to reach around 10% during FY2026 and at least 20% in FY2027.

That potential margin expansion means earnings could increase substantially faster than revenue if management achieves its targets.

4. US Manufacturing Expansion

OXB has expanded its US manufacturing footprint through its facility in Durham, North Carolina.

The company describes the US as the epicentre of cell and gene therapy development, estimating that approximately half of global cell-and-gene-therapy programmes are located there.

Having manufacturing capacity close to major biotechnology customers could strengthen OXB's competitive positioning and help win larger programmes.

5. Continued Cell and Gene Therapy Development

OXB's underlying opportunity depends on continued investment in cell and gene therapies.

Its September 2025 interim results cited 2,210 cell and gene therapies in the global clinical pipeline, up from 2,068 a year earlier.

A larger development pipeline can ultimately create more demand for viral-vector process development and manufacturing services.

FY2026 Growth Outlook

OXB's current financial guidance represents a substantial step up from FY2025.

Management expects £220–240 million of FY2026 revenue, with an Operating EBITDA margin around 10%.

However, investors should be aware of the expected timing of that revenue.

Management has indicated that FY2026 revenue and EBITDA are expected to be second-half weighted, partly because of technology transfers and the ramp-up of the Durham facility.

This makes the upcoming H1 trading update particularly interesting.

A weaker first-half number would not automatically mean the full-year target is in trouble because management has already signalled that a larger proportion of activity is expected later in the year.

Why Is the Durham Facility Important?

The Durham operation strengthens OXB's presence in the world's largest biotechnology market.

The company has highlighted three strategic benefits: proximity to major US clients, additional commercial-scale manufacturing capacity and completion of a more comprehensive end-to-end manufacturing network.

The opportunity is therefore not simply additional physical capacity.

If the facility attracts new customers and allows existing customers to expand programmes, it could contribute to revenue growth while increasing utilisation across OXB's manufacturing network.

Key Growth Catalysts

Cell and Gene Therapy Pipeline Expansion

More therapies entering clinical development can create additional demand for specialised viral-vector manufacturing.

New Customer Wins

CDMO contracts can become significant if a customer's therapy progresses from clinical development toward commercial manufacturing.

Durham Facility Ramp-Up

Higher utilisation of OXB's expanded US manufacturing capacity could support both revenue and margins.

Margin Expansion

Management's trajectory from around 10% Operating EBITDA margin in FY2026 toward at least 20% in FY2027 is one of the most important financial catalysts to monitor.

FY2027–28 Growth

OXB expects 25–30% year-on-year revenue growth in both 2027 and 2028, ahead of its expectations for the broader market.

If achieved, that would demonstrate that the current growth phase extends well beyond 2026.

Risks

Biotechnology funding: OXB's customers depend partly on access to capital to fund clinical-development programmes.

Programme failures: Clinical programmes can be delayed, discontinued or fail to obtain regulatory approval, potentially reducing manufacturing demand.

Customer concentration: Large contracts can make individual customer programmes important to revenue.

Capacity utilisation: OXB has invested significantly in manufacturing infrastructure. Lower-than-expected demand could leave capacity underutilised and pressure margins.

Execution risk: The company must successfully ramp up its expanded international manufacturing network.

Second-half weighting: FY2026 expectations depend heavily on stronger activity later in the year, increasing the importance of execution during H2.

Valuation

Oxford Biomedica requires a somewhat different valuation approach from a mature pharmaceutical company.

Relevant measures include:

  • Enterprise Value-to-Revenue
  • Enterprise Value-to-EBITDA
  • Revenue backlog
  • Revenue growth
  • Operating EBITDA margin
  • Free cash flow
  • Capacity utilisation
  • Customer and programme growth

The most important valuation question may be whether OXB can successfully translate rapid revenue expansion into sustainable margins and cash flow.

A company growing revenue rapidly but operating with low margins deserves a different valuation from one capable of combining 25–30% growth with 20%+ EBITDA margins.

OXB's FY2027 target of at least a 20% Operating EBITDA margin is therefore particularly important.

Outlook

The medium-term outlook for Oxford Biomedica PLC (LSE:OXB) is centred on rapid growth combined with significant operating leverage.

The company expects FY2026 revenue of £220–240 million, followed by 25–30% annual revenue growth in FY2027 and FY2028. At the same time, management expects Operating EBITDA margins to increase from around 10% in 2026 to at least 20% in 2027.

Longer term, OXB sees margin potential approaching approximately 30% as its expanded manufacturing capacity becomes more fully utilised.

For today (28 July 2026), however, I could not verify a fresh material OXB announcement that directly explains the 1.93% share-price increase you provided.

The stock's rise is therefore better viewed against the backdrop of strong growth expectations, anticipation of the upcoming H1 trading update, US manufacturing expansion and expectations for substantial margin improvement.

The next important company-specific catalyst is likely to be the Half Year 2026 Trading Update, which OXB currently lists for July/August, followed by formal H1 results on 22 September.